Compare Macy's Inc (M) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Neurocrine Biosciences Inc — how do they compare? Macy's Inc trades at $22.79 (market cap $5.95B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.4× Macy's Inc's market cap, and Macy's Inc pays a 3.36% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Neurocrine Biosciences Inc for 23 Days on average.
| M | NBIX | |
|---|---|---|
Market Cap | $5.95B | $14.36B |
Volume | 11,329,747 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $185.50 |
52-Week Low | $16.51 | $123.10 |
Typical Hold Time | 58 Days | 23 Days |
Enterprise Value | $9.75B | $14.37B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.79, up 1.47% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals, with Q2 2026 EPS beating estimates and a raised 2026 outlook. Valuation remains attractive with a P/E of 8.35 and P/S of 0.27, while cash flow trends have strengthened, with net cash flow turning positive in 2024 and 2025. Recent news highlights progress in the 'Bold New Chapter' strategy, focusing on digital and omnichannel growth.
The outlook for Macy's is cautiously optimistic, supported by cheap valuations and strategic initiatives, but risks include competitive pressures and uneven earnings growth. Analyst consensus is mixed with a $24.25 price target, indicating modest upside potential. Key investment opportunities lie in dividend yield and turnaround execution, while risks involve margin pressure and macroeconomic headwinds affecting retail demand.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
